In Brief: EndoVascular Technologies
This article was originally published in The Gray Sheet
EndoVascular Technologies: Initial Phase II study results for the firm's bifurcated EGS endovascular grafting system to treat abdominal aortic aneurysm released June 2 demonstrate a 49% decrease in hospital stay with EGS use versus standard AAA surgery. Mean hospital stay was 3.9 days for the EGS group versus 7.6 days for surgical controls. The 209 patient study included 106 EGS patients and 103 surgical control patients treated at 20 U.S. sites. Results showed that for EGS patients, the prosthesis "was successfully delivered and implanted in 96 of 106 attempted procedures, representing 90.6% primary technical success," the firm states. "The 30-day mortality rate" for the EGS group patients was 1.9% versus 3.9% for the surgical control group. Serious complications were seen in 1.9% of EGS patients and 2.9% of surgical controls. Results of the firm's tube EGS system Phase II studies were reported in January ("The Gray Sheet" Jan. 20, I&W-6)...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.